Integrative genomic and proteomic analyses identify targets for Lkb1 deficient metastatic lung tumors
NAGIOS: RODERIC FUNCIONANDO

Integrative genomic and proteomic analyses identify targets for Lkb1 deficient metastatic lung tumors

Repositori DSpace/Manakin

Integrative genomic and proteomic analyses identify targets for Lkb1 deficient metastatic lung tumors

Mostra el registre complet de l'element

Visualització       (4.512Mb)

Exportar a Refworks
    
Carretero, Julian; Shimamura, Takeshi; Rikova, Klarisa; Jackson, Autumn L.; Wilkerson, Matthew D.; Borgman, Christa L.; Buttarazzi, Matthew S.; Sanofsky, Benjamin A.; McNamara, Kate L.; Brandstetter, Kathleyn A.; Walton, Zandra E.; Gu, Ting-Lei; Silva, Jeffrey C.; Crosby, Katherine; Shapiro, Geoffrey I.; Maira, Michel; Ji, Hongbin; Castrillon, Diego H.; Kim, Carla F; García-Echeverría, Carlos; Bardeesy, Nabeel; Sharpless, Norman E.; Hayes, Neil D.; Kim, William Y.; Engelman, Jeffrey A.; Wong, Kwok-Kin
Aquest document és un/a article, creat/da en: 2010
SummaryIn mice, Lkb1 deletion and activation of KrasG12D results in lung tumors with a high penetrance of lymph node and distant metastases. We analyzed these primary and metastatic de novo lung cancers with integrated genomic and proteomic profiles and have identified gene and phosphoprotein signatures associated with Lkb1 loss and progression to invasive and metastatic lung tumors. These studies revealed that SRC is activated in Lkb1 deficient primary and metastatic lung tumors and that the combined inhibition of SRC, PI3K and MEK1/2 resulted in synergistic tumor regression. These studies demonstrate that integrated genomic and proteomic analyses can be used to identify signaling pathways that may be targeted for treatment.

    Vol. 17 Issue 6: pp. 547-559
distribuït sota llicència Creative Commons de Reconeixement-NoComercial 3.0 No adaptada

Aquest element apareix en la col·lecció o col·leccions següent(s)

Mostra el registre complet de l'element

Cerca a RODERIC

Cerca avançada

Visualitza

Estadístiques